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Abstract 
Background: Clinical features and outcomes of patients with spontaneous ilio-psoas hematoma (IPH) in intensive 
care units (ICUs) are poorly documented. The objectives of this study were to determine epidemiological, clinical, 
biological and management characteristics of ICU patients with IPH.
Methods: We conducted a retrospective multicentric study in three French ICUs from January 2006 to December 
2014. We included IPH diagnosed both at admission and during ICU stay. Surgery and embolization were available 
24 h a day for each center, and therapeutic decisions were undertaken after pluridisciplinary discussion. All IPHs were 
diagnosed using CT scan.
Results: During this period, we identified 3.01 cases/1000 admissions. The mortality rate of the 77 included patients 
was 30 %. In multivariate analysis, we observed that mortality was independently associated with SAPS II (OR 1.1, 95 % 
CI [1.013–1.195], p = 0.02) and with the presence of hemorrhagic shock (OR 67.1, 95 % CI [2.6–1691], p = 0.01). We 
found IPH was related to anticoagulation therapy in 56 cases (72 %), with guideline-concordant reversal performed in 
33 % of patients. We did not found any association between anticoagulant therapy type and outcome.
Conclusion: We found IPH is an infrequent disease, with a high mortality rate of 30 %, mostly related to anticoagula-
tion therapy and usually affecting the elderly. Management of anticoagulation-related IPH includes a high rate of no 
reversal of 38 %.
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Background
Ilio-psoas hematoma (IPH) is defined as a spontaneous 
or traumatic retroperitoneal collection of blood involv-
ing the ilio-psoas muscle. Even if the precise occurrence 
of spontaneous IPH remains uncertain, mostly because 
a few studies are available, incidence of retroperitoneal 
bleeding in patients undergoing anticoagulation has been 
reported ranging from 0.1 to 0.6 % [1].
Risk factors for spontaneous retroperitoneal hematoma 
are anticoagulation therapy, the elderly and hemodialysis 
[2]. Whereas precise pathogenesis and pathophysiology 
of retroperitoneal bleeding is unknown, it is hypothesized 
that retroperitoneal microvascular atherosclerosis could 
increase sensitivity to rupture, with an involvement of 
large vessels if stretched by the enlarging hematoma. 
Anticoagulation and microtrauma such as cough or vom-
iting could also lead to retroperitoneal bleeding. Never-
theless, theses theories are not confirmed on histology.
Whether incidental diagnosis is frequent, clinical pres-
entation depends on the severity of the hemorrhage, 
varying from compressive symptoms, such as nerve palsy 
or ischemia, to lower pain and/or anemia [3]. CT scan is 
the main tool for diagnosis, providing useful information 
on volume, spatial extent, compressive complications or 
active bleeding [4, 5].
Incidence of IPH in the intensive care is unknown. 
Most of the time, these patients usually need hemody-
namic and/or respiratory support and blood transfusion 
[6]. Given the lack of evidences, there is no consensus on 
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therapeutics, and each decision, i.e., conservative treat-
ment, embolization, surgical or CT scan-guided hemato-
ma’s drainage, is made by weighting risks and benefits [7].
We conducted a multicentric retrospective study of 
patients with a diagnosis of spontaneous IPH in the 
intensive care in order to assess incidence, fate, manage-
ment and outcome of these patients.
Methods
Patients
We retrospectively included patients with IPH admitted 
in three French academic intensive care units (Cochin 
Hospital, Versailles Hospital and Georges Pompidou 
European Hospital) from January 2006 to December 
2014. There is no reference center for IPH within the 
Paris metropolitan area, and these three centers were 
selected because they manage both medical and surgi-
cal patients and because surgery and embolization were 
available 24 h a day for each center. There was no consen-
sual guideline to manage IPH among the three hospitals. 
Patients were evaluated, and the severity was assessed by 
a senior intensivist in the emergency department or in a 
medical department of the hospital for each center prior 
to ICU admission.
Data collection
For every center, we screened all admitted patients from 
January 2006 to December 2014 and cases were identi-
fied using informatics medical charts with the following 
keywords “psoas,” “iliac,” “ilio-psoas,” “bleed” and “hema-
toma,” We included every patient of 18 years old or more 
presenting a non-traumatic IPH, and we excluded trau-
matic causes of IPH. Patients with IPH admitted from 
other centers in order to perform open surgery and/or 
embolization were excluded. Data retained were patient’s 
demographics, initial prognosis, severity at admission, 
medical history, laboratories and imaging investigations, 
and intra-hospital course. Patient’s characteristics and 
preexisting conditions were abstracted from the medi-
cal charts. Simplified Acute Physiology Score II (SAPS 
II), Sequential Organ Failure Assessment (SOFA) score, 
heart rate, mean arterial pressure and temperature were 
computed at diagnosis of the IPH. Hemorrhagic shock 
was defined according to international criteria as hemo-
dynamic instability defined by systolic arterial blood 
pressure (SAP)  <  90  mmHg or signs of shock and the 
presence of a life-threatening bleeding or bleeding that 
compromises vital function [8]. Liver failure was defined 
as a factor V  <  50  % or the presence of jaundice and 
acute kidney injury as an increase in serum creatinine 
by 26.5 μmol/l within 48 h or an increase up to 1.5 times 
baseline [9]. IPH was related to anticoagulant treatment 
in patients treated with vitamin K antagonist (VKA), low 
molecular weight heparin (LMWH) or unfractionned 
heparin (UH) regardless of the presence of an over-anti-
coagulation, as defined in guidelines [10]. CT scan with 
contrast enhancement was performed for each patient. 
Blood and derived products were transfused accord-
ing to physician judgment. Therapeutic decisions were 
undertaken after pluridisciplinary discussion involving 
surgeons and intensivists. Surgery and embolization were 
available 24 h a day for each center.
Statistical analysis
Quantitative parameters and continuous data are pre-
sented as median and interquartile range (IQR, 25th–
75th percentile) and were compared between groups 
using nonparametric U Mann–Whitney test. Qualitative 
parameters are presented as counts and percentage. Cat-
egorical variables were compared using the Chi-square 
test or Fischer’s exact test, as appropriate. A multivariate 
analysis was performed to identify independent factors 
using a binomial logistic regression. Variables included in 
the multivariate analysis were those significant (p < 0.05) 
in univariate analysis, and we calculated the odds ratio 
(OR) associated and its 95 % confidence interval (CI). All 
P value was two-tailored, and statistical significance was 
set at p  <  0.05. All statistical analyses were carried out 
with SPSS® version 20.0.
Results
The study flowchart is shown in Fig. 1. Between January 
2006 and December 2014, among 25,576 patients admit-
ted in ICU, we retained 77 patients having an ilio-psoas 
hematoma, corresponding to 3.01 cases/1000 admissions 
during this period. Main clinical patient’s characteristics 
and preexisting conditions at ICU admission are sum-
marized in Table 1. Fifty patients were admitted in ICU 
for IPH management, whereas the diagnosis of IPH was 
made in 27 ICU patients previously hospitalized, with a 
median time of 7 days (IQR 3.5–17). Median age at diag-
nosis was 72 years (IQR 64.8–79), and 31 patients were 
female (40 %). Thirty-four patients presented with hem-
orrhagic shock (44  %) at diagnosis. CT scan was per-
formed in every patient, with an active arterial bleeding 
diagnosed in 29  % of patients (n  =  22) and compres-
sion of adjacent structures diagnosed in 34 % of patients 
(n = 26). The mortality rate was 30 % (n = 23), with no 
difference across centers.
Data concerning management of patient are sum-
marized in Table  2. Vasopressive support and mechani-
cal ventilation were more frequently performed in died 
patients than in survivors (87 vs. 39 %, p > 0.001 and 96 
vs. 50 %, p  > 0.001, respectively). Whether conservative 
treatment was less frequently performed in died patients 
when compared to the survivors (78 vs. 48 % respectively, 
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OR 0.24, 95 % CI [0.08–0.68], they underwent more fre-
quently surgery (26 vs. 2  % respectively, OR 18.7, 95  % 
CI [2.1–166.5]). In multivariate analysis (Table  3), we 
observed that mortality was independently associated 
with SAPS II (OR 1.1, 95 % CI [1.013–1.195], p = 0.02) 
and with the presence of hemorrhagic shock (OR 67.1, 
95 % CI [2.6–1691], p = 0.01).
We found IPH was related to anticoagulant therapy in 
56 cases (72  %), with 21 cases of vitamin K antagonists 
(VKA) therapy, 23 cases of unfractionated heparin (UH) 
therapy and 12 cases of low molecular weight heparin 
(LMWH) therapy. Patients were on anticoagulant ther-
apy for the following reasons: atrial fibrillation (n = 18), 
deep venous thrombosis (n = 14), pulmonary embolism 
(n = 13), prosthetic heart valve (n = 7), stroke (n = 1) and 
acute myocardial infarction (n =  3). Among anticoagu-
lated patients, 11 patients were previously treated with 
aspirin and 8 patients received a combination of aspirin 
and clopidogrel for coronary artery disease, with no dif-
ference in mortality. We found no difference on mortality 
in patients having or not an anticoagulation treatment.
Regardless of administration time, the guideline con-
cordant recommended co-administration of vitamin 
K and prothrombin complex concentrate at appropri-
ate doses in VKA-related hematoma accounted for 33 % 
of patients in the whole cohort (Table  4). Protamine 
reversal was performed in 13 % (n = 3) of patients with 
UH-related hematoma and in 1 survivor patient with 
LMWH-related hematoma. Among 34 patients with 
Fig. 1 Flowchart of the study: patients with ilio-spoas hematoma
Table 1 Clinical characteristics at diagnosis
OR odds ratio, 95 % CI 95 % confidence interval, SOFA Sequential Organ Failure Assessment score, SAPS II score Simplified Acute Physiology Score II
Clinical characteristic at diagnosis All (n = 77) Died (n = 23) Alive (n = 54) p value OR 95 % CI of OR
Age, years 72 (64.8–79) 71 (69–81) 72 (63–78) ns
Female sex, n (%) 31 (40) 10 (43) 21 (39) ns
Preexisting conditions
 Hypertension, n (%) 45 (58) 17 (74) 28 (52) ns
 Smoking, n (%) 27 (35) 5 (22) 22 (41) ns
 Body mass index, kg/m2 27 ± 6 27 ± 4 27 ± 6 ns
 Chronic cardiac failure, n (%) 24 (31) 6 (26) 18 (33) ns
 Diabetes, n (%) 10 (13) 4 (17) 6 (11) ns
 Renal insufficiency, n (%) 18 (23) 4 (17) 14 (26) ns
 Peripheral vascular disease, n (%) 14 (18) 6 (26) 8 (15) ns
 Cirrhosis, n (%) 2 (2) 1 (4) 1 (2) ns
 Cancer or hematological malignancy, n (%) 25 (32) 7 (30) 18 (33) ns
  Remission, n 9 3 (13) 6 (11) ns
  Evolutive, n 16 4 (17) 12 (22) ns
Glasgow Coma Scale 15 (11.5–15) 11 (3–15) 15 (14–15) 0.04
SOFA score 6 (3.5–10) 10 (5–15) 5 (3–8) <0.001
SAPS II score 56 (36.5–59) 75 (57–95) 48 (31–60) <0.001
Clinical presentation, n (%)
 Hemorrhagic shock 34 (44) 22 (95) 12 (22) <0.001 77 (9.3–631)
 Compressive symptoms 20 (25) 5 (21) 15 (27) ns
 Abdominal bruises 23 (29) 6 (26) 17 (31) ns
 Incidental diagnosis on CT scan 11 (14) 3 (13) 8 (15) ns
Heart rate, beats per minute 94 ± 25 100 ± 32 93 ± 22 ns
Mean arterial pressure, mmHg 83 ± 20 71 ± 19 83 ± 20 0.02
Temperature, °C 37 (36–37.4) 36.1 (35–37.2) 37 (36.7–37.6) 0.01
Hemoglobin. g/dL 7.5 (6.4–9.2) 7.3 (5.8–8.7) 7.7 (6.6–9.4) ns
Lactate at admission, mmol/L 2.2 (1.4–7.3) 7.8 (2.6–11.8) 1.9 (1.1–3.8) <0.001
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hemorrhagic shock at admission, 24 are related to antico-
agulation therapy and only 9 (37 %) are reversed.
Discussion
In the following cohort, we found that IPH is an infre-
quent pathology with 77 cases identified on 25,576 
admissions between January 2006 and December 2014. 
To our knowledge, this is the first report of incidence of 
admission in ICU. In a large observational cohort study 
of severe hemorrhage in 822 VKA-treated patients, 
bleeding was located in deep muscle and in the subperi-
toneal area in 13  % [11]. Moreover, in a retrospective 
study of 180 patients presenting a spontaneous retro-
peritoneal hematoma, 62  % of patients were admitted 
in ICU [12]. The relative low proportion of IPH among 
global ICU patients we observed in our study may be 
partly explained by the fact that retroperitoneal bleeding 
accounts for a small part of overall severe bleeding, and 
patients are scarcely admitted in ICU.
We found IPH was related to VKA therapy in 21 
patients (27  %), with no reversal treatment in 38  % and 
with no guideline-concordant reversal in 29 %. According 
to guidelines, reversal treatment of severe bleeding under 
VKA therapy consists in restoring iso-coagulation with 
an INR < 1.5 as soon as possible. It is recommended to 
perform a prompt reversal using at least 20 IU/kg factor 
IX equivalent prothrombin complex concentrate (PCC) 
and at least 5 mg of vitamin K performed within a prede-
fined time frame of 8 h after admission [10]. Regardless 
of administration time, in our study the guideline-con-
cordant co-administration of PCC and vitamin K was 
performed in one-third of patients. It is well established 
that many factors may influence the implementation of a 
guideline in practice such as individual patient, the indi-
vidual healthcare provider and the organizational context 
[13]. In the context of our study, various barriers may 
explain this low adherence rate to guideline-concordant 
reversal such as the fear of thrombosis in case of normal 
Table 2 Management in the ICU of the overall cohort of IPH
OR odds ratio, 95 % CI 95 % confidence interval
Management in the ICU All (n = 77) Died (n = 23) Alive (n = 54) p value RR 95 % CI of OR
Acute heart failure, n (%) 11 (14) 6 (26) 5 (9) ns
Vasopressive support during the first 24 h, n (%) 39 (51) 21 (91) 18 (33) <0.001 17.8 (3.7–84.2)
 Norepinephrine, n 25 16 9
 Epinephrine, n 11 5 6
 Dobutamine, n 5 2 3
Liver failure (factor V < 50 % or jaundice), n (%) 16 (21) 12 (52) 4 (7) <0.001 1.6 (3.6–50)
Acute kidney injury, n (%) 42 (55) 19 (83) 23 (43) 0.001 6.4 (1.9–21.3)
 Dialysis, n 19 10 9
 Hemofiltration, n 4 2 2
 Renal recovery at ICU discharge, n 14 1 13
 Duration of renal replacement therapy, days 15.8 ± 16.9 18.1 ± 21.1 5.3 ± 5.4 0.01
Mechanical ventilation, n (%) 49 (63) 22 (96) 27 (50) <0.001 22 (2.7–175)
Duration of mechanical ventilation, days 3 (0–10.5) 6 (2–21) 1 (1–8) 0.002
Packed red blood cell transfusion, units 4 (2–6) 6 (3–8) 3(2–5) 0.002
Conservative treatment, n (%) 53 (69) 11 (48) 42 (78) 0.007 0.24 (0.08–0.68)
Surgery, n (%) 7 (9) 6 (26) 1 (2) 0.002 18.7 (2.1–166.5)
Embolization, n (%) 17 (22) 6 (26) 11 (20) ns
Table 3 Multivariate predictors of intensive care unit mortality in patients with IPH
b slope, se standard error, df degrees of freedom, OR odds ratio, 95 % CI 95 % confidence interval
Variables b se Wald test df OR 95 % CI for OR p value
Hemorrhagic shock 4.206 1.646 6.527 1 67.1 2.663–1691 0.011
SAPS II score 0.095 0.042 5.092 1 1.1 1.013–1.195 0.024
Lactate 0.262 0.149 3.091 1 1.3 0.97–1.741 0.079
Duration of mechanical ventilation 0.052 0.032 2.615 1 1.054 0.989–1.123 0.106
Number of packed red blood cells transfused 0.531 0.287 3.413 1 1.701 0.968–2.988 0.065
Conservative treatment 0.207 1.101 0.035 1 1.23 0.142–10.65 0.851
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INR or the unawareness of guidelines by the physicians. 
Among 34 patients with hemorrhagic shock at admis-
sion, 24 are related to anticoagulation therapy and only 9 
(37 %) are reversed, thus suggesting that reversal does not 
depend on the practitioner’s perception of the severity. 
This low proportion of reversal in anticoagulated patients 
presenting with hemorrhagic shock may explain in part 
their frequent fatal outcome. In multivariate analysis, the 
presence of hemorrhagic shock is independently associ-
ated with mortality. This association highlights the fact 
that prognosis is intrinsically and closely linked to the 
bleeding and emphasizes the importance of a rapid and 
appropriate management of the blood loss.
This study shows that IPH is associated with a 30  % 
mortality rate in the ICU. Whether a precise descrip-
tion of usual mortality of IPH in ICU is not reported in 
the literature, this can be roughly approximated by some 
studies. Mortality ranges from 12 to 19 % [12, 14], with 
various admission rates in ICU (62 and 40  %, respec-
tively). In 29 patients, Guivarc’h et al. reports a mortal-
ity of 3 %, with surgery performed in 88 % of cases [15]. 
However, in this cohort, only 28 % were under excessive 
anticoagulation and only 4 patients were hemodynami-
cally unstable. Beside the ICU, mortality of deep-muscle 
VKA-related hematoma in the emergency department 
can be as low as 4  % [11]. We herein observe a higher 
mortality, thus suggesting patients admitted in ICU have 
a worse prognosis at admission than patients previously 
reported in the literature. Consistently, classical markers 
of severity, such as lactate level, SAPS II or SOFA score, 
are high in non-survivor patients in our cohort.
Management of life-threatening psoas hematoma, 
and more widely of soft tissue hemorrhage, in anti-
coagulated patients remains controversial. Whether 
conservative treatment is recommended in hemody-
namically stable patient with no evidence of ongoing 
bleeding, the usefulness of embolization or surgery in 
case of bleeding is far from being demonstrated. Sur-
gery seems to be indicated when the patient remains 
unstable despite medical resuscitation, if interven-
tional radiology is not successful or unavailable or in 
case of abdominal compartment syndrome [2]. Open 
surgery consists in identification and control of the 
bleeding source, evacuation of the hematoma and 
packing of the muscular compartment, with a reex-
ploration at 24–48  h [16]. We observed open surgery 
was performed in our study as a salvage therapy in 
uncontrolled patients after maximal medical treatment 
failure and is not associated in univariate analysis with 
a good outcome. In contrast, even when there is no sig-
nificant statistical association, embolization seems to 
be useful for the investigation of active bleeding and 
its treatment. In a recent retrospective cohort of 36 
patients presenting with anticoagulation-related soft 
tissue bleeding, with 21 hematoma located in the ilio-
psoas compartment, embolization is efficient and safe 
for selective arterial embolization. However, the over-
all mortality in this cohort was 30  %, with a rebleed-
ing rate of 25 % [17]. Thus, even if evidences are scarce, 
interventional treatment should be considered rapidly 
in the management of severe IPH.
CT scan is easily and quickly performed and provides 
useful information such as the localization, evidences 
for an ongoing bleeding or compression on adjacent 
structures. Furthermore, another main advantage of 
this imaging modality is its ability to deduce both origin 
and arterial or venous source of the bleeding. Therefore, 
it appears important to perform CT scan with contrast 
enhancement rapidly in the management of IPH.
One of the main limits of our study is the retrospec-
tive character of the cohort and the sample size that did 
not allowed us to draw solid association through a strong 
multivariate analysis. The multivariate analysis we herein 
performed should be taken cautiously given the small 
population, the importance of hemorrhagic shock in 
the results and the unavoidable association and overlap 
of covariates considered in analysis. Because the review 
of medical charts using keywords is prone to bias, we 
could have underestimated the true incidence of IPH 
in the overall population by having omitted the one or 
other case out. Addition of patients from other ICU so 
as the screening of surgical ICU could increase the num-
ber of patients and strengthen the power of this work. 
Moreover, we cannot precise the timing for reversal of 
Table 4 Anticoagulated-related hematoma: reversal man-
agement
Anticoagulated-related hematoma All Died Alive p value
VKA-related hematoma, n 21 5 16
 Reversal management
  No reversal, n (%) 8 (38) 1 (20) 7 (44) ns
  No guideline-concordant reversal, n (%)6 (29) 2 (40) 4 (25) ns
  Guideline-concordant reversal, n (%) 7 (33) 2 (40) 5 (31) ns
 INR at diagnosis
  Normal (INR < 1.5), n (%) 0 (0) 0 (0) 0 (0) ns
  Therapeutic (INR between 1.5 and 4), 
n (%)
8 (38) 3 (50) 5 (33) ns
  Supratherapeutic (INR > 4), n (%) 9 (57) 1 (17) 8 (53) ns
  Missing values, n (%) 4 (19) 2 (33) 2 (13) ns
Unfractionned heparin-related hematoma, 
n
23 6 17
 Protamine reversal, n (%) 3 (13) 1 (17) 2 (12) ns
Low molecular weight heparin-related 
hematoma, n
12 3 9
 Protamine reversal, n (%) 1 (8) 0 (0) 1 (11) ns
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coagulopathy that may influence the outcome if per-
formed to late.
Conclusion
We found IPH is an infrequent disease, with a high mor-
tality rate, mostly related to anticoagulation therapy and 
usually affecting the elderly. Management of anticoagu-
lation-related IPH includes a high rate of no reversal of 
38 %. We believe that prospective studies should permit 
to further identify parameters associated with mortality 
and to determine whether surgery or embolization is an 
efficient therapeutic approach.
Authors’ contributions
JFL and JPM participated in the design of the study and in data collection, 
performed the statistical analysis and participated in drafting the manuscript. 
FD and DG participated in the design of the study and in data collection and 
helped to draft the manuscript. SL, EG, JPB and JYF helped in data collection 
and data analysis and to draft the manuscript. JLG participated in the design 
of the study and helped to perform the statistical analysis. JC participated in 
the design of the study and data collection and analysis and in drafting the 
manuscript. All authors read and approved the final manuscript.
Author details
1 Medical Intensive Care Unit, Cochin Hospital, Groupe Hospitalier Cochin 
Broca Hôtel-Dieu, Assistance Publique des Hôpitaux de Paris, 27 rue du 
Faubourg Saint-Jacques, 75014 Paris, France. 2 Faculté de Médecine, Uni-
versité Paris Descartes, Sorbonne Paris Cité, 15 rue de l’Ecole de Médecine, 
75006 Paris, France. 3 Intensive Care Unit, Hôpital de Versailles - Site André 
Mignot, 177 rue de Versailles, 78150 Le Chesnay Cedex, France. 4 Cardiology, 
Hôpital de Versailles - Site André Mignot, 177 rue de Versailles, 78150 Le Ches-
nay Cedex, France. 5 Medical Intensive Care Unit, Hôpital Européen Georges 




The authors declare that they have no competing interests.
Received: 28 June 2015   Accepted: 4 January 2016
References
 1. Estivill Pallejà X, Domingo P, Fontcuberta J, Félez J. Spontaneous retroperi-
toneal hemorrhage during oral anticoagulant therapy. Arch Intern Med. 
1985;145(8):1531–4.
 2. Chan YC, Morales JP, Reidy JF, Taylor PR. Management of spontaneous 
and iatrogenic retroperitoneal haemorrhage: conservative manage-
ment, endovascular intervention or open surgery? Int J Clin Pract. 
2008;62(10):1604–13.
 3. González C, Penado S, Llata L, Valero C, Riancho JA. The clinical spectrum 
of retroperitoneal hematoma in anticoagulated patients. Medicine (Balti-
more). 2003;82(4):257–62.
 4. Lindner A, Zierz S. Images in clinical medicine. Retroperitoneal hemor-
rhage. N Engl J Med. 2001;344(5):348.
 5. Scialpi M, Scaglione M, Angelelli G, Lupattelli L, Resta MC, Resta M, et al. 
Emergencies in the retroperitoneum: assessment of spread of disease by 
helical CT. Eur J Radiol. 2004;50(1):74–83.
 6. Beloncle F, Meziani F, Lerolle N, Radermacher P, Asfar P. Does vasopressor 
therapy have an indication in hemorrhagic shock? Ann Intensive Care. 
2013;3(1):13.
 7. Hunt BJ. Bleeding and coagulopathies in critical care. N Engl J Med. 
2014;370(9):847–59.
 8. Bouglé A, Harrois A, Duranteau J. Resuscitative strategies in traumatic 
hemorrhagic shock. Ann Intensive Care. 2013;3(1):1.
 9. Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evalu-
ation, and management of acute kidney injury: a KDIGO summary (Part 
1). Crit Care Lond Engl. 2013;17(1):204.
 10. Pernod G, Godiér A, Gozalo C, Tremey B, Sié P, French National Authority 
for Health. French clinical practice guidelines on the management of 
patients on vitamin K antagonists in at-risk situations (overdose, risk of 
bleeding, and active bleeding). Thromb Res. 2010;126(3):e167–74.
 11. Tazarourte K, Riou B, Tremey B, Samama C-M, Vicaut E, Vigué B, et al. 
Guideline-concordant administration of prothrombin complex concen-
trate and vitamin K is associated with decreased mortality in patients 
with severe bleeding under vitamin K antagonist treatment (EPAHK 
study). Crit Care Lond Engl. 2014;18(2):R81.
 12. Shah RD, Nagar S, Shanley CJ, Janczyk RJ. Factors affecting the severity of 
spontaneous retroperitoneal hemorrhage in anticoagulated patients. Am 
J Surg. 2008;195(3):410–2 (discussion 412–3).
 13. Lugtenberg M, Burgers JS, Besters CF, Han D, Westert GP. Perceived barri-
ers to guideline adherence: a survey among general practitioners. BMC 
Fam Pract. 2011;12:98.
 14. Sunga KL, Bellolio MF, Gilmore RM, Cabrera D. Spontaneous retroperito-
neal hematoma: etiology, characteristics, management, and outcome. J 
Emerg Med. 2012;43(2):e157–61.
 15. Guivarc’h M. Hematoma of the iliac psoas muscle. 29 cases. J Chir (Paris). 
1997;134(9–10):382–9.
 16. Finlay IG, Edwards TJ, Lambert AW. Damage control laparotomy. Br J Surg. 
2004;91(1):83–5.
 17. Dohan A, Sapoval M, Chousterman BG, di Primio M, Guerot E, Pellerin O. 
Spontaneous soft-tissue hemorrhage in anticoagulated patients: safety 
and efficacy of embolization. AJR Am J Roentgenol. 2015;204(6):1303–10.
